Parallel Evolution under Chemotherapy Pressure in 29 Breast Cancer Cell Lines Results in Dissimilar Mechanisms of Resistance

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Retraction Note to: Retraction: Genomic signatures to guide the use of chemotherapeutics

(2011) Anil Potti et al.   NATURE MEDICINE

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

(2010) M Gerlinger et al.   BRITISH JOURNAL OF CANCER

Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients

(2010) Fabrice Andre et al.   CURRENT OPINION IN ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials

(2010) Everardo D. Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

(2010) Yang Li et al.   NATURE MEDICINE

Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines

(2009) Cornelia Liedtke et al.   BREAST CANCER RESEARCH AND TREATMENT

PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer

(2009) G Munkácsy et al.   BRITISH JOURNAL OF CANCER

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

(2009) Pierre Farmer et al.   NATURE MEDICINE